Advertisement

Topics

PD-L1 Inhibitor Wins NSCLC Indication

14:32 EDT 18 Oct 2016 | MedPageToday

(MedPage Today) -- Atezolizumab for postplatinum, non-EGFR, non-ALK tumors

Original Article: PD-L1 Inhibitor Wins NSCLC Indication

NEXT ARTICLE

More From BioPortfolio on "PD-L1 Inhibitor Wins NSCLC Indication"

Quick Search
Advertisement